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Abstract
Background: NORE1 (RASSF5) is a newly described member of the RASSF family with Ras effector function. NORE1
expression is frequently inactivated by aberrant promoter hypermethylation in many human cancers, suggesting
that NORE1 might be a putative tumor suppressor. However, expression and mutation status of NORE1 and its
implication in colorectal tumorigenesis has not been evaluated.
Methods: Expression, mutation, and methylation status of NORE1A and NORE1B in 10 cancer cell lines and 80
primary tumors were characterized by quantitative PCR, SSCP, and bisulfite DNA sequencing analyses. Effect of
NORE1A and NORE1B expression on tumor cell growth was evaluated using cell number counting, flow cytometry,
and colony formation assays.
Results: Expression of NORE1A and NORE1B transcript was easily detectable in all normal colonic epithelial tissues,
but substantially decreased in 7 (70%) and 4 (40%) of 10 cancer cell lines and 31 (38.8%) and 25 (31.3%) of 80
primary carcinoma tissues, respectively. Moreover, 46 (57.6%) and 38 (47.5%) of 80 matched tissue sets exhibited
tumor-specific reduction of NORE1A and NORE1B, respectively. Abnormal reduction of NORE1 was more commonly
observed in advanced stage and high grade tumors compared to early and low grade tumors. While somatic
mutations of the gene were not identified, its expression was re-activated in all low expressor cells after treatment
with the demethylating agent 5-aza-dC. Bisulfite DNA sequencing analysis of 31 CpG sites within the promoter
region demonstrated that abnormal reduction of NORE1A is tightly associated with promoter CpG sites
hypermethylation. Moreover, transient expression and siRNA-mediated knockdown assays revealed that both
NORE1A and NORE1B decrease cellular growth and colony forming ability of tumor cells and enhance tumor cell
response to apoptotic stress.
Conclusion: Our data indicate that epigenetic inactivation of NORE1 due to aberrant promoter hypermethylation is
a frequent event in colorectal tumorigenesis and might be implicated in the malignant progression of colorectal
tumors.
Background
Mutational activation of Ras plays a critical role in the
development and malignant progression of many human
tumors [1,2]. Ras oncoproteins participate in the regula-
tion of a broad range of biological processes, including
cell growth and differentiation, membrane trafficking,
transcriptional regulation and apoptosis [2,3]. Ras pro-
teins exist in an inactive GDP-bound and an active
GTP-bound conformation, and in the active GTP-bound
state, Ras functions by binding and modulating the
activity of a diverse array of effector proteins, such as
Raf kinases, RalGEFs, and phosphatidylinositol 3-kinases
[3,4]. Recently, new genes encoding the Ras-association
(RA) domain have been identified, and termed the Ras-
association domain family (RASSF) [5,6]. RASSF proteins
interact either directly or indirectly with activated Ras
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naling pathways associated with tumor cell growth [7].
Among 8 RASSF genes identified, RASSF1 was the most
well-characterized tumor suppressor, which exhibits a
frequent epigenetic inactivation in various types of
human neoplasms, including lung and breast cancers
[6-11]. RASSF1 encodes several isoforms (RASSF1A-C),
which are derived from alternative mRNA splicing and
promoter usage. Transcriptional silencing of RASSF1A
was observed in a considerable proportion of lung,
breast, ovarian, and nasopharyngeal cancers by de novo
methylation at the CpG islands in the promoter [8-11].
In small cell lung cancers, allelic loss of 3p21.3 was
associated with RASSF1A methylation, suggesting that
both genetic and epigenetic mechanisms are implicated
in RASSF1A inactivation in some tumor types [9]. In
addition, RASSF1A was identified to suppress the
growth of tumor cells in both in vitro and in vivo,a n d
Ras regulates pro-apoptotic pathway through its interac-
tion with RASSF1A [5,8,12].
NORE1 (RASSF5), a human homologue of the mouse
Ras effector Nore1, is newly identified member of the
RASSF family [13,14]. The NORE1 gene is located on
chromosome 1q32.1, and two major transcripts
(NORE1A and NORE1B) are derived from different pro-
moter usage [14]. NORE1A is epigenetically inactivated
by promoter hypermethylation in various cancer cell
lines and primary tumors, including lung, breast, and
kidney tumors [15,16]. It was also found that NORE1A
mediates Ras-dependent apoptosis, and its reintroduc-
tion in defective cell lines impairs tumor cell growth in
soft agar and suppresses colony formation [12,17-19].
Interestingly, it was reported that the proapoptotic effect
of RASSF1 may require heterodimerization with
NORE1A [20]. Very recently, it was identified that
NORE1A activates the cyclin-dependent kinase inhibitor
p21
WAF1 via promoting p53 nuclear localization, and
loss of NORE1A expression correlates with loss of
p21
WAF1 in human hepatocellular carcinoma [21]. All of
these studies suggest that NORE1A might be a putative
tumor suppressor in human cancers.
In the present study, we investigated the expression
and mutation status of two NORE1 isoforms, NORE1A
and NORE1B in a series of primary colorectal carcinoma
tissues and cancer cell lines to explore its candidacy as a
tumor suppressor in colorectal tumorigenesis. Our data
demonstrate that expression of NORE1A and NORE1B
is abnormally down-regulated in a substantial fraction of
colorectal cancer cell lines and primary carcinomas by
aberrant promoter hypermethylation. Furthermore,
altered expression of NORE1 correlated with tumor
stage and grade. We also found that both NORE1A and
NORE1B exert growth suppression effect via inhibition
of cellular growth and colony formation of tumor cells
and enhancement of cellular response to apoptotic
stress. Together, our data suggest that inactivation of
NORE1 m a yp l a yac r i t i c a lr o l ei nt h em a l i g n a n tp r o -
gression of colorectal tumors.
Methods
Human colorectal cancer cell lines and tissue specimens
Ten human colon cancer cell lines (Caco2, Colo320,
HCT116, SW403, SW620, DLD-1, WiDr, SNU-C1,
SNU-C4, and SNU-C5) were obtained from American
Type Culture Collection (Rockville, MD, USA) and
Korea Cell Line Bank (Seoul National University, Seoul,
Korea). Cell lines were maintained at 37°C in RPMI
1640 or DMEM medium supplemented with 10% fetal
bovine serum (FBS) (GIBCO BRL, Carlsbad, CA, USA).
A total of 80 primary colorectal tumor specimens and
their adjacent normal tissues were obtained by surgical
resection in the Kyung Hee University Medical Center
(Seoul, Korea). Tissue specimens were snap-frozen
immediately in liquid N2 and stored at -80°C until used.
Signed informed consent was obtained from each
patient. Bits of primary tumors and adjacent portions of
each tumor were fixed and used for hematoxylin and
eosin staining for histopathological evaluation. Tumor
specimens composed of at least 70% carcinoma cells
and adjacent tissues found not to contain tumor cells
were chosen for molecular analysis.
Semiquantitative reverse transcription (RT)- and DNA-
polymerase chain reaction (PCR) analysis
Total cellular RNA was extracted from tissues and cell
lines by standard method. One μg of DNase1-treated
RNA was converted to cDNA by reverse transcription
using random hexamer primers and MoMuLV reverse
transcriptase (Life Technologies, Inc., Gaithersburg, MD,
USA). PCR was initially performed over a range of
cycles (24, 26, 28, 30, 32, 34, 36, and 38 cycles) and 2 μl
of 1:4 diluted cDNA (12.5 ng/50 μl PCR reaction)
undergoing 28-36 cycles was observed to be within the
logarithmic phase of amplification with primers
NORE1-10 (sense: 5’-CAGTTGGACTGCAGTCAGCA-
3’) and NORE1-9 (antisense: 5’-GGAGAGTTTCTG
GAAGAGCA-3’)f o rNORE1A,N O R E 1 - 5( s e n s e :5 -
CATGAGCAGTGGGTACTGCA-3’)a n dN O R E 1 - 9f o r
NORE1B,a n dG 2( s e n s e ;5 ’- CATGTGGGCCAT
GAGGTCCACCAC-3’) and G3 (antisense; 5’-AACCAT
GAGAAGTATGACAACAGC-3’) for an endogenous
expression standard gene GAPDH.P C Rp r i m e r sf o r
NORE1A and NORE1B were designed to amplify the
transcript regions of exons 2a-5 and 2b-5, respectively.
PCR was done for 34 cycles at 95°C (1 min), 58-62°C
(0.5 min), and 72°C (1 min) in 1.5 mM MgCl2-contain-
ing reaction buffer (PCR buffer II, Perkin Elmer). For
genomic PCR analysis, 200 ng of genomic DNA, which
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DNA phase after RNA was extracted, were used for
amplification of the exon 2 region of NORE1 with
intron-specific primers G-RSF5-S (sense; 5’-
GCGTGCGGGGAGACCGCAGTCT-3’)a n dG - R S F 5 -
AS (antisense; 5’-CTCCCAAGAACTCACAACAAA-3’).
Ten μl of PCR products were resolved on 2% agarose
gels. Quantitation was achieved by densitometric scan-
ning of the ethidium bromide-stained gels. Absolute
area integrations of the curves representing each speci-
men were then compared after adjustment for GAPDH
level. Integration and analysis was performed using
Molecular Analyst software program (Bio-Rad, Hercules,
CA, USA). Semi-quantitative PCR was repeated at least
three times for each specimen and mean level was
calculated.
Immunoblotting analysis
Cells were lysed in a lysis buffer containing 20 mM Tris
(pH 7.4), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxy-
cholate, 0.1% sodium dodecyl sulfate (SDS), 50 mM
sodium fluoride, 2 mM sodium pyrophosphate, 1 mM
sodium orthovanadate, protease inhibitor cocktail, and 1
mM PMSF. The cell lysate was clarified by centrifuga-
tion and 20 to 50 μg of total protein was supplemented
with Laemmli buffer and loaded on an 8% SDS-polya-
crylamide gel for electrophoresis. Immunoblotting ana-
lyses were performed using antibodies specific for
NORE1A (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and Actin (Santa Cruz Biotechnology). Antibody
binding was detected by enhanced chemiluminescence
(Santa Cruz Biotechnology) using a secondary antibody
conjugated to horseradish peroxidase. For reprobing
with other antibodies, the membranes were incubated in
a stripping buffer (0.2M glycine pH 2.2, 0.1% SDS, 1%
Tween-20) at 50°C for 60 min.
Nonisotopic PCR-single strand conformation
polymorphism (SSCP) analysis
To detect possible sequence alterations in NORE1,w e
performed nonisotopic PCR-SSCP analysis. The NORE1
gene was amplified with 7 sets of primers that were
designed to cover the entire coding region of the gene.
The PCR products of over 300 bp in lengths were
digested with endonuclease(s) to increase the sensitivity
of SSCP analysis. Twenty μlo fP C Rp r o d u c t sw e r e
mixed with 10 μlo f0 . 5NN a O H ,1 0m ME D T A ,a n d
15 μl of denaturing loading buffer (95% formamide, 20
mM EDTA, 0.05% bromophenol blue, and 0.05% xylene
cyanol). After heating at 95°C for 5 min, samples were
loaded in wells pre-cooled to 4°C and run using 9%
nondenaturating acrylamide gels containing 10% glycerol
at 4-8°C and 18-22°C.
5-Aza-2’-deoxycytidine (5-Aza-dC) and TSA (Trichostantin A)
treatment
To assess reactivation of NORE1 expression, cell lines
showing no or low levels of NORE1A and/or NORE1B
transcripts were plated in six-well tissue plates 48 h
before treatment. 5-Aza-dC (Sigma, St. Louis, MO,
U S A )w a sa d d e dt ot h ef r e s hm e d i u ma tc o n c e n t r a t i o n
of 1, 5, and 10 μM in duplicate and cells were harvested
after 5 days. To evaluate effect of TSA on NORE1
expression, cells were incubated with 5-Aza-dC for 48 h
and then treated with TSA (Sigma) at concentration of
250 ng/ml for 48 h.
Bisulfite DNA sequencing analysis
Fifty ng of bisulfite-modified DNA was subjected to PCR
amplification of the NORE1A promoter region using pri-
mers MS-NORE3 (5’-AAAGAGGCAGGGCTGAAG-
GACCTAGG-3’) and MS-NORE6 (antisense; 5’-
CCGATGGCCGGGGACGCCATGGCC-3’). The PCR
products were cloned into pCRII vectors (Invitrogen,
Carlsbad, CA, USA) and 5 clones of each specimen
were sequenced by automated fluorescence-based DNA
sequencing to determine the methylation status.
Construction of expression plasmids, siRNA and
transfection
Expression vectors encoding wild-type NORE1A and
NORE1B were constructed by a PCR based approach
using primers NORE1A-S (sense; 5’-ATGGC-
CATGGCGTCCCCGGC-3’) and NORE1-AS (antisense;
5’-CCCAGGTTTGCCCTGGGATT-3’)f o rN O R E 1 A
and NORE1B-S (sense; 5’-ATGACCGTGGACAGCAG-
CAC-3’) and NORE1-AS for NORE1B. The PCR pro-
ducts were cloned into pEF6/V5-His-TOPO expression
vector (Invitrogen, Carlsbad, CA, USA). Transfection of
expression plasmids was performed using Effectene
(QIAGEN, Hilden, Germany) according to the instruc-
tion of manufacturer. Briefly, 1 × 10
5 cells were trans-
fected with plasmids-Effectene mixture for 4 h. The
transfected cells were incubated with RPMI1640 med-
i u mw i t h1 0 %s e r u mf o ri n d i c a t e dd u r a t i o n .D e t e c t a b l e
toxicity and apoptosis by reagent or vectors was rare.
Each transfection experiment was carried out in tripli-
cate. The transfection efficiency was monitored using a
CAT assay (Roche, Mannheim, Germany) according to
the instruction of manufacturer. Small interfering RNA
(siRNA) duplex against NORE1A (5’-GCGCUGCA-
CUAACUGUAAA-3’), NORE1B (5’-GCGCAGAG-
CAAACAUCUUU-3’) and control siRNA duplex which
served as negative control were synthesized by Invitro-
gen (Carlsbad, CA, USA). For transfection, 1 × 10
5 cells
were plated on 60-mm-diameter dishes 24 h and incu-
bated with a siRNA-Oligofectamine mixture at 37°C for
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was added and incubated for 20 h.
Cell proliferation and apoptosis analysis
Cells were seeded in 6-well plate at the density of 1 ×
10
5 cells per well in duplicate and were maintained in
the presence of 10% FBS. The following day, cells were
transfected with expression vector or siRNA as
described above. Cell numbers were counted using a
hemocytometer for 4 days at 24 h intervals. For flow
cytometry analysis, cells were harvested 48 h after trans-
fection and fixed with 70% ethanol and resuspended in
1 ml of PBS containing 50 mg/ml RNase and 50 mg/ml
propidium iodide (Sigma, S t .L o u i s ,M O ,U S A ) .F o r
apoptosis analysis, the cells were treated with 25 μMo f
etoposide for 24 h and fraction of apoptotic sub G1
phase was determined using a FACScan flow cytometry
and Modfit software (Becton Dickinson, San Jose, CA,
USA).
Colony formation assay
Caco-2 cells (1 × 10
5 )w e r et r a n s f e c t e dw i t h2μgo f
expression vectors encoding WT-NORE1A, WT-
NORE1B or empty vector (pcDNA3.1). HCT116 cells
were transfected with 20 pM of siNORE1A, siNORE1B
or siControl. The transfected cells were maintained in
the presence of G418 (400 ng) for 7 days. Colonies were
fixed with methanol for 15 min and stained with 0.05%
crystal violet in 20% ethanol.
Statistical analysis
A student’s t-test was used to determine the statistical
significance of the difference. The Chi-square test was
used to determine the statistical significance of expres-
sion and methylation levels between tumor and normal
tissues. A P value of less than 0.05 was considered
significant.
Results
Frequent reduction of NORE1 expression in primary
carcinoma tissues and cancer cell lines
To explore whether NORE1 alteration is implicated in
colorectal tumorigenesis, we initially determined expres-
sion levels of NORE1 transcripts in 80 noncancerous tis-
sues and 10 cancer cell lines using semi-quantitative
RT-PCR analysis. Expression of NORE1A and NORE1B
transcripts was easily detectable in all noncancerous tis-
sues tested and its levels showed no significant varia-
tions among the specimens (Figure 1A). By contrast,
variable levels of NORE1 transcripts were observed in
cancer cell lines (Figure 1B). Compared to noncancerous
tissues, 70% (7 of 10) and 40% (4 of 10) of cell lines
exhibited substantial reduction of NORE1A and
NORE1B, respectively. Four cell lines (Caco-2, Colo320,
SNU-C1 and SW403) showed low expression of both
transcripts. Except WiDr, which has a NORE1A-specific
reduction, cancer cell lines showed similar pattern in
expression of NORE1A and NORE1B,s u g g e s t i n gt h a t
mRNA expression of NORE1A and NORE1B might be
similarly controlled or affected in colorectal cancer cells.
NORE1A and/or NORE1B transcripts in Caco-2,
Colo320 and WiDr were detected only by nested PCR,
indicating that these cancer cells expressed extremely
low levels of the transcripts. An immunoblot assay using
anti-NORE1A antibody revealed that protein levels of
NORE1A are well consistent with its mRNA levels (Fig-
ure 1B). Together, these results demonstrate that both
NORE1A and NORE1B expression is frequently down-
regulated in colorectal cancer cells at the transcript
level, and NORE1A is more commonly down-regulated
compared to NORE1B. Likely cancer cell lines, primary
tumors expressed variable levels of NORE1A and
NORE1B, and a substantial fraction of tumors showed a
marked reduction in expression of both transcripts (Fig-
ure 1C). In addition, among 80 matched tissue sets we
examined, 46 (57.6%) and 38 (47.5%) cases revealed
tumor-specific reduction (>40% reduction compared to
corresponding normal tissues) of NORE1A and
NORE1B, respectively while none of matched sets dis-
played tumor-specific elevation of the transcripts (Figure
1D). While 6 of 80 (7.5%) tumors showed NORE1A-spe-
cific reduction, none of primary tumors exhibited
NORE1B-specific reduction. Except these 6 cases,
expression status of NORE1A and NORE1B was fairly
similar in the same tumors. These results indicate that
down-regulation of NORE1 expression is a tumor-speci-
fic phenomenon and NORE1A m i g h tb eam o r ec o m -
mon target for inactivation in colorectal tumorigenesis.
Association of NORE1 reduction with tumor progression
To explore the significance of NORE1 reduction in
cancers, its expression levels were compared between
noncancerous tissues, primary carcinoma tissues, and
cancer cell lines. Semi-quantitative PCR was repeated
at least three times for each specimen and mean levels
were obtained. As shown in Figure 2A, mean of
expression levels in normal tissues, primary cancers,
and cancer cell lines, was determined as 1.28, 0.82, and
0.41 for NORE1A and 1.18, 0.83, and 0.71 for
NORE1B, respectively. Expression levels of both tran-
scripts were significantly low in primary cancers and
cancer cell lines compared to that of normal tissues
(P < 0.01). We arbitrarily set a value less than a half of
normal mean (0.64 for NORE1A and 0.59 for
NORE1B) as abnormally low level. Based on this cri-
teria, 31 (38.8%) and 25 (31.3%) of 80 primary carci-
noma tissues and 7 (70%) and 4 (40%) of 10 cancer
cell lines were classified as abnormally low expressors
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Likely cancer cell lines, all of low NORE1B tumors (25
of 25, 100%) were identified to have low NORE1A
level, showing that NORE1A reduction is a more com-
mon than NORE1B reduction in colorectal cancers
(Figure 2B). Furthermore, NORE1A reduction was sig-
nificantly high in stage III tumor (19 of 36, 52.8%)
compared with stage I and II tumors (7 of 26, 26.9%
and 5 of 18, 27.8%, respectively) (P < 0.05) and more
frequent in poorly differentiated tumors (6 of 9, 66.7%)
than well and moderately differentiated tumors (9 of
25, 36% and 16 of 46, 34.8%, respectively) (P < 0.05)
(Figure 3A). Likewise, NORE1B reduction was signifi-
cantly frequent in stage III tumors (15 of 36, 41.7%)
compared with stage I and II tumors (5 of 26, 19.2%
and 5 of 18, 27.8% and) (P < 0.05) and more common
in poorly differentiated tumors (6 of 9, 66.7%) than
well and moderately differentiated tumors (6 of 25,
24.0% and 13 of 46, 28.3%, respectively) (P < 0.05).
However, NORE1 expression showed no association
with age and gender of the patients (data not shown).
Based on a previous report demonstrating that
Figure 1 Expression status of NORE1A and NORE1B in human colorectal tissues and cancer cell lines. Expression of NORE1A and NORE1B
mRNA in normal colorectal epithelial tissues (A). Semi-quantitative RT-PCR was performed using exon-specific primers and 10 μl of the PCR
products were resolved on a 2% agarose gel. GAPDH was used as an endogenous control. Frequent reduction of NORE1A and NORE1B
expression in colorectal cancer cell lines (B). An immunoblting assay was performed using NORE1A-specific antibody and chemiluminescence
detection. Expression of NORE1A and NORE1B in primary colorectal carcinoma tissues (C). Tumor-specific reduction of NORE1A and NORE1B
expression (D). NORE1 expression in tumor (T) and adjacent noncancerous (N) tissues were compared using matched tissue sets obtained from
the same patients (P).
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Page 5 of 15Figure 2 Quantitative analysis of NORE1 mRNA levels in colorectal cancer cell lines and tissue specimens.E x p r e s s i o nl e v e l so fNORE1A
and NORE1B in colorectal tissues and cell lines (A). Quantitation was achieved by densitometric scanning of RT-PCR products in ethidium
bromide-stained gels. Absolute area integrations of the curves representing each specimen were compared after adjustment for GAPDH. Data
represent means of triplicate assays (Bars, SD) Bar indicates the mean expression level of each specimen group. Expression status of NORE1A and
NORE1B in matched tumor sets (B). Expression levels of NORE1A and NORE1B were compared between cancerous and adjacent noncancerous
tissues from the same patients. Semi-quantitative RT-PCR was repeated at least three times for each specimen (*, P < 0.05).
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evaluated the possible association of NORE1 reduction
with the mutational status of K-Ras in primary carci-
noma tissues. The presence of K-Ras mutation was
determined by SSCP and subsequent DNA sequencing
analysis of K-Ras exonic regions comprising of codons
12, 13, and 61. K-Ras mutations were found in 30 of
80 (37.5%) primary tumors, but showed no significant
correlation with NORE1 expression (Figure 3B).
Together, these results indicate that abnormal reduc-
tion of NORE1 expression is associated with the malig-
nant progression of colorectal tumors.
Re-activation of NORE1 expression by 5-Aza-dC treatment
To define whether NORE1 reduction in cancers was
caused by loss of the gene itself, genomic level of
NORE1 was examined using quantitative genomic PCR
in 10 cancer cell lines. However, none of the cell lines
Figure 3 Association of NORE1 alteration with tumor progression. Correlation of NORE1 r e d u c t i o nw i t ht u m o rs t a g ea n dg r a d e( A ) .
Expression levels of NORE1A and NORE1B were compared between stages I, II, and III tumors, and between well differentiated (WD), moderately
differentiated (MD), and poorly differentiated (PD) tumors. No association of NORE1A and NORE1B expression with K-Ras mutation in primary
colorectal tumors (B). The mutational status of K-Ras in 80 primary carcinoma tissues was determined by SSCP and DNA sequencing analysis.
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ure 4A). Likewise, no difference in NORE1 gene level
was recognized between cancer and adjacent noncancer-
ous tissues from 80 matched tissue sets (Figure 4B). To
examine the mutational status of the gene, 10 cancer
cell lines and 40 primary carcinoma tissues were sub-
jected to PCR-SSCP analysis using 7 primer sets which
cover the entire coding region of NORE1.H o w e v e r ,w e
failed to find any types of mutation leading to amino
acid substitution (data not shown). These observations
indicate that genomic deletion and mutation of NORE1
is not common and may not be associated with abnor-
mal reduction of NORE1 expression in colorectal can-
cers. Next we tested whether NORE1 down-regulation is
associated with by DNA hypermethylation. Cancer cell
lines with low NORE1 level were treated with the
demethylating agent 5-Aza-dC and the histone deacety-
lation inhibitor Trichostantin A and its effect on tran-
script expression was determined by RT-PCR analysis.
Our initial test using two cell lines (Caco-2 and
Colo320) demonstrated that expression of NORE1A and
NORE1B is re-activated by 5-Aza-dC treatment in a
dose-associated manner and its levels are further ele-
vated in the presence of TSA (Figure 4C). As shown in
Figure 4D, we observed that transcript levels of
NORE1A and NORE1B are markedly increased in all
low expressor cell lines following 5-Aza-dC treatment,
indicating that NORE1 expression is down-regulated in
these cancer cells at the transcription level by abnormal
DNA hypermethylation.
Aberrant promoter CpG sites hypermethyation of
NORE1A in colorectal cancers
To elicit whether tumor-specific reduction of NORE1
expression is caused by the aberrant promoter hyper-
methylation, the methylation status of 31 CpG sites
located within the proximal region of the NORE1A pro-
moter was characterized (Figure 5A and 5B). Bisulfite
DNA sequencing was performed for 10 cell lines and 6
matched tissue sets showing tumor-specific reduction of
NORE1A transcript levels. Five PCR clones from each spe-
cimen were randomly selected to determine methylation
frequency at individual CpG sites (complete methylation;
4-5 clones, partial methylation; 1-3 clones, unmethylation;
0 clone). As summarized in Figure 5C, a strong correlation
between methylation frequency and transcript level was
found in cancer cell lines. Interestingly, the majority of the
21 CpG sites (CpG site numbers 11-31) was completely or
partially methylated in cancer cell lines showing low level
of expression (Caco2, Colo320, SNU-C1, SW403, SW620,
and WiDr), while only 3-5 (9.7-16.1%) sites were partially
methylated in cell lines showing strong expression (DLD-1
and HCT116). SNU-C4 cells, which express an intermedi-
ate level of NORE1A transcript, showed only partial
methylation at 12 CpG sites. Likewise, 6 primary tumors
with low transcript level showed methylation at 16-24
(51.6-77.4%) sites, whereas methylation was very rare (0-3
sites) in its adjacent noncancerous tissues (Figure 5D).
Therefore, these results clearly demonstrate that aberrant
promoter CpG sites hypermethylation is tightly associated
with decreased expression of NORE1 transcript in colorec-
tal cancers.
Inhibition of tumor cell growth by NORE1A and NORE1B
To define the roles for NORE1 in tumor growth, we
initially evaluated effects of its expression on cellular
growth using ectopic expression of wild-type (WT)-
NORE1A and WT-NORE1B in Caco-2 and siRNA-
mediated knockdown of endogenous NORE1A and
NORE1B expression in HCT116. Transfection of WT-
NORE1 and siNORE1 led to a dose-associated induction
and knockdown of NORE1, respectively (Figure 6A and
6C). Cell number counting assay showed that cellular
growth of Caco-2 is suppressed by expression of
NORE1A or NORE1B, and growth of HCT116 is facili-
tated by knockdown of NORE1A or NORE1B (Figure
6B and 6D). Compared to empty vector-transfected con-
trol, cellular growth of Caco-2 showed approximately
29.5% and 18.0% reduction at 4 days after transfection
of WT-NORE1A and WT-NORE1B, respectively. Like-
wise, cellular growth of HCT116 exhibited approxi-
mately 24.6% and 7.7% increase by transfection of
siNORE1A and siNORE1B, respectively. These results
indicate that both NORE1A and NORE1B exert growth
inhibition effect and NORE1A might have more potent
anti-proliferative ability compared to NORE1B in color-
ectal epithelial cells. A flow cytometric analysis of the
sub G1 phase revealed that expression of NORE1A and
NORE1B enhances both baseline (pcDNA 0.98%, WT-
NORE1A 6.98%, and WT-NORE1B 6.46%) and etopo-
side-induced apoptosis (pcDNA 23.2%, WT-NORE1A
40.9%, WT-NORE1B 37.4% in 2 μg transfection) (Figure
7 Aa n d7 B ) .S i m i l a r l y ,i nH C T 1 1 6c e l l s ,e t o p o s i d e -
induced apoptosis was significantly decreased by knock-
down of NORE1A or NORE1B (Figure 7C and 7D). The
apoptotic response of both Caco-2 and HCT116 cells to
etoposide was up- and down-regulated by restoration
or knockdown of NORE1A and NORE1B in a dose-
associated manner. Consistent with these, ectopic
expression of NORE1A and NORE1B led to approxi-
mately 58.3% and 37.9% decrease in colony forming
ability of Caco-2 cells while knockdown of NORE1A
and NORE1B caused approximately 61.3% and 32.3%
increase in colony forming ability of HCT116 cells,
further demonstrating that both NORE1A and NORE1B
have growth suppression activities (Figure 7E).
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Page 8 of 15Figure 4 Genomic status of NORE1 and re-activation by 5-Aza-dC. Genomic level of NORE1 in colorectal cancer cell lines (A). The NORE1
gene was amplified by genomic PCR using intron-specific primer sets. Ten μl of the PCR products were resolved on a 2% agarose gel. GAPDH
was used as an endogenous control. Comparison of NORE1 gene level between tumor and adjacent noncancerous tissues (B). Effect of 5-Aza-dC
and TSA on NORE1A and NORE1B mRNA expression (C). Caco-2 and Colo320 cells were treated with increasing doses of 5-Aza-dC for 4 days. For
combined treatment with TSA, the cells were incubated with 5-Aza-dC for 48 h and then exposed to TSA (250 ng/ml) for 48 h. Elevation of
NORE1A and NORE1B mRNA expression in low expressor cell lines following 5-Aza-dC treatment (D). Cancer cell lines with low NORE1 level were
treated with 5-Aza-dC (5 μM) for 5 days and NORE1A and NORE1B expression was evaluated by RT-PCR analysis. C, untreated control; T, 5-Aza-dC
treated.
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Page 9 of 15Figure 5 Methylation status of CpG sites in the NORE1A promoter. A map of the CpG sites within the proximal region of the NORE1A
promoter (A). CpGs sites are represented by vertical lines. The transcription start site is indicated by an arrow at +1. Nucleotide sequences of
NORE1A promoter region examined by bisulfite DNA sequencing analysis (B). Thirty one CpG sites (bold) examined are numbered 1-31 and
primers for PCR were indicated. The ATG start codon is indicated (boxed). Methylation status of 31 CpG sites in the NORE1A promoter and its
association with mRNA level in colorectal cancer cell lines (C). The promoter region comprised of 31 CpGs was amplified by PCR. The PCR
products were cloned and 5 plasmid clones were sequenced for each cell line. Percent methylation was determined by the number of alleles
containing a methylated CpG at each position. Black, gray, and white squares represent complete methylation (4-5 clones), partial methylation
(1-3 clones), and unmethylation (0 clone), respectively. Comparison of CpG sites methylation between primary tumors and adjacent
noncancerous tissues (D). N, noncancerous tissue; T, tumor tissue; P, patient.
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Page 10 of 15Figure 6 Suppression of tumor cell growth by NORE1A and NORE1B. Transient transfection of expression vectors encoding WT-NORE1A
and WT-NORE1B in Caco-2 cells (A). A dose-associated expression of NORE1A and NORE1B was determined at 72 h post-transfection using semi-
quantitative RT-PCR. Suppression of Caco-2 cell growth by NORE1A or NORE1B (B). Caco-2 cells were transfected with 2 μg of WT-NORE1A or
WT-NORE1B and cell numbers were counted at 24 h intervals. The assay was performed in triplicate (*, P < 0.05). SiRNA-mediated knockdown of
NORE1 expression in HCT116 cells (C). The cells were transfected with increasing doses of siRNA and NORE1A and NORE1B levels were
determined by RT-PCR at 72 h post-transfection. Anti-proliferative role of endogenous NORE1A and NORE1B (D). HCT116 cells were transfected
with 50 nM of siNORE1A, siNORE1B or siControl and cell numbers were counted at 24 h intervals. The assay was performed in triplicate (*, P <
0.05). Suppression of colony formation of tumor cells by NORE1 (E). Caco-2 and HCT116 cells transfected with 2 μg of expression vectors or
siRNA were maintained in the presence of G418 (400 ng) for 7 days. The assay was performed in triplicate (*, P < 0.05; **, P < 0.01).
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In the present study, we demonstrated that expression
of NORE1A and NORE1B is down-regulated at the tran-
scription level in a substantial fraction of colorectal can-
cer cell lines and primary carcinomas. Abnormal
reduction of NORE1A and NORE1B was identified to be
at u m o r - s p e c i f i cp h e n o m e non and correlated with
advanced stage and high grade of tumors. In both estab-
lished cell lines and primary tumors, downregulation of
NORE1A expression was tightly associated with aberrant
promoter CpG sites hypermethylation. Moreover,
NORE1A and NORE1B were found to suppress cellular
growth and colony forming ability of tumor cells and
enhance tumor cell response to apoptotic stress,
Figure 7 Anti-apoptotic function of NORE1A and NORE1B. Effect of NORE1 expression on baseline and etoposide-induced apoptosis (A, B).
Caco-2 cells were transfected with WT-NORE1A or WT-NORE1B and percentage of sub G1 phase was determined by flow cytometric analysis.
Caco-2 cells transfected with WT-NORE1 were treated with etoposide (25 μM, 24 h). Effect of NORE1 knockdown on etoposide-induced
apoptosis (C, D). HCT116 cells transfected with siNORE1 were treated with etoposide (25 μM, 24 h).
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Page 12 of 15indicating that both NORE1 isoforms have growth sup-
pression functions. Collectively, these results suggest
that epigenetic silencing of NORE1 might contribute to
the malignant progression of human colorectal cancers.
Chromosome 1q32 region exhibits loss of heterozyg-
osity in many types of human cancer including colorec-
tal cancer, thus suggested to harbor tumor suppressor
genes [22,23]. NORE1 was predicted as a target of dele-
tion at 1q32.1, and allelic loss of the gene was suggested
as a plausible mechanism underlying its low expression
in tumor cells [13]. In this study, however, genomic ana-
lysis of NORE1 revealed that deletion or sequence
alteration of NORE1 is very rare in cancers, suggesting
that genomic deletion of the gene might not be a main
cause leading to loss or abnormal reduction of its
expression in colorectal cancers.
Hypermethylation in CpG-rich region is strongly asso-
ciated with transcriptional silencing, and hypermethyla-
tion at CpG sites in transcription regulatory region is a
critical event leading to the epigenetic inactivation of
tumor suppressor genes [24,25]. Hypermethylation of
the NORE1 gene has been reported in several cancers,
including breast, lung, kidney, and colorectal cancers
[15,26]. It was also reported that epigenetic alteration of
NORE1A is confined to lung tumors with a wild-type K-
Ras, suggesting that epigenetic inactivation of NORE1A
and mutational activation of K-Ras might play a coop-
erative role in lung tumorigenesis [27]. In the present
study, we found that expression of both NORE1A and
NORE1B is frequently decreased in primary colorectal
carcinoma tissues as well as cancer cell lines. However,
no association was identified between expression status
of NORE1A or NORE1B and mutational status of K-Ras
in 80 primary carcinomas specimens we examined.
Interestingly, abnormal reduction of NORE1A was more
frequent compared to that of NORE1B and none of cell
l i n e sa n dp r i m a r yt u m o r ss h o w e dNORE1B-specific
reduction, suggesting that NORE1A might be a more
critical target of inactivation in colorectal tumorigenesis.
Expression of both NORE1 isoforms was re-activated in
cell lines by treatment with 5-Aza-dC and the NORE1A
promoter was identified to be aberrantly hypermethy-
lated in cancer cell lines and primary tumors expressing
low levels of NORE1A transcript. Methylation frequency
of 31 CpG sites in the proximal region of NORE1A pro-
moter was much higher in tumors showing low mRNA
expression compared to adjacent noncancerous tissues
with normal mRNA level. Moreover, the methylation
levels in both cancer cell lines and primary tumors
showed a tight correlation with mRNA expression sta-
tus. In particular, aberrant methylation of 21 CpG sites
(numbered 11-31, Figure 5B) was most tightly associated
with gene silencing, indicating that CpG dinucleotides in
this region may play an important role for the regulation
of NORE1A transcription. Therefore, our data support
that NORE1 is epigenetically inactivated in a substantial
fraction of colorectal cancers, and CpG sites hyper-
methylation of the 5’ u p s t r e a mr e g i o no ft h eg e n ei s
crucial for its transcriptional silencing. It could be
assumed that the hypermethylation of CpG sites in this
region might block the access of cis-acting transcription
factors to their binding sequences presumably by direct
inhibition of binding or through the establishment of a
repressed chromatin structure at the methylated CpG
island [28,29].
Although NORE1 has been identified as a potential
tumor suppressor, the biological function of NORE1
and the significance of its inactivation during tumori-
genesis have not been well understood. Previous studies
showed that NORE1A mediates Ras-dependent apopto-
sis and suppresses tumor cell growth and colony forma-
tion, and the proapoptotic effect of RASSF1 requires the
heterodimerization with NORE1A [12,17-20]. In the
present study we demonstrated that cellular growth and
colony forming capability of colorectal cancer cells are
significantly suppressed and their responses to apoptotic
stress are markedly increased by expression of either
NORE1A or NORE1B, indicating that both NORE1A
and NORE1B have growth suppression abilities. Transi-
ent expression and siRNA-mediated knockdown assays
revealed that compared to NORE1B, NORE1A evokes
more potent growth inhibition effects in two different
cells. Although further molecular analyses are required,
this finding might correlate with our expression data
supporting that NORE1A is a more critical target of
inactivation in colorectal tumorigenesis. Interestingly, a
recent study demonstrated that NORE1A activates the
cyclin-dependent kinase inhibitor p21
WAF1 via promot-
ing p53 nuclear localization, and loss of NORE1A
expression correlates with tightly with loss of p21
WAF1
in human hepatocellular carcinoma [21]. Considering
that p21
WAF1 is a crucial target of p53-mediated cell
cycle arrest, this finding raises the interesting possibility
that NORE1A could be a potential component, which
plays an important role in functional connection
between Ras and p53 signaling [21]. Although we did
not evaluate the possible role of NORE1 in p53 signal-
ing, our finding of the significant growth suppression of
mutant p53-carrying Caco-2 cells by NORE1A or
NORE1B indicates that both NORE1A and NORE1B
have p53-independent growth arrest and apoptosis-
enhancing functions. It has been well known that onco-
genic activation of Ras and mutational inactivation of
p53 play a critical role in colorectal tumorigenesis. In
this context, expression status of NORE1 and its asso-
ciation with activation status of Ras and p53 could pro-
vide valuable information for the molecular mechanisms
underlying colorectal tumor progression. In the present
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Page 13 of 15study, we observed that reduced expression of NORE1 is
associated with histopathological characteristics of
tumors, such as tumor stage and grade. However, no
association was recognized between expression of
NORE1A or NORE1B and mutation of K-Ras.I nc o n -
trast to cancerous tissues, abnormal reduction or pro-
moter hypermethylation of NORE1 was not found in
corresponding nonneoplastic mucosa. Based on previous
reports that DNA methylation occurs early in the multi-
step process of carcinogenesis [30-32], our data raises
the possibility that epigenetic inactivation of NORE1
might be implicated in the development and/or early
progression of colorectal tumors.
Conclusions
Both NORE1 and NORE1B is significantly down-
regulated in a considerable fraction of colorectal cell
lines and primary tumors by aberrant DNA hypermethy-
lation, and its abnormal reduction correlates with
advanced stage and higher grade of tumor. Restored
expression of NORE1A or NORE1B decreases cellular
growth and colony forming ability of colorectal tumor
cells and enhances cellular response to apoptotic stress.
T h e s ef i n d i n g st h u ss u g g e s tt h at epigenetic inactivation
of NORE1 might play a crucial role in the malignant
progression of colorectal tumors, possibly by providing
selective growth advantage for colorectal epithelial
tumor cells.
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